Immunomedics says epratuzumab produced 'durable complete responses' in lymphoma |
|
|
|
Published
:
Mon, 10 Dec 2007 20:27
|
SAN FRANCISCO (Thomson Financial) - Immunomedics Inc. said Monday its lead product candidate, epratuzumab, produced 'durable complete responses' in patients with recurrent or refractory non-Hodgkin's lymphoma, or NHL, when used in combination with rituximab.'These final results confirm that adding epratuzumab to rituximab did not produce additive toxicity over that expected with rituximab alone, and the combination therapy was well tolerated by patients,' said Dr. John P. Leonard, lead investigator of the study, in a statement. 'This study demonstrates promising anti-lymphoma activity for indolent NHL, and can result in durable complete remissions in a significant subset of patients.'The data was presented at the 49th annual meeting of American Society of Hematology in Atlanta.Shares of the Morris Plains, N.J.-based biopharmaceutical company were down 6 cents at $2.84.Katherine Huntkh/jwCOPYRIGHTCopyright Thomson Financial News Limited 2007. All rights reserved.The copying, republication or redistribution of Thomson Financial News Content, including by framing or similar means, is expressly prohibited without the prior written consent of Thomson Financial News.
|
|
|
|
Print this Story
Immunomedics says milatuzumab shows promise in preclinical studies 